A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)

This is a Phase I/II, multi-center, open-label, randomized, parallel group, pharmacokinetic,
pharmacodynamic study of the AG1000-6.5 and AG1000-12.5 transdermal contraceptive delivery
systems (TCDS) in healthy women followed as an outpatient for up to three 28-day cycles (12
weeks or approximately 3 months). During this study, subjects will receive active treatment
with the LNG TCDS patches for 11 weeks, followed by one week of post-treatment assessment.
The TCDS is designed for one week of patch wear. This study will be conducted by the National
Institute of Child Health and Human Development (NICHD) in its Contraceptive Clinical Trials
Network (CCTN) at 6 sites in the USA and will enroll approximately 120 women.

This study will enroll approximately 120 subjects, who will be randomized across all sites
into the two treatment groups (~60 subjects at each dose level). The randomization schedule
will be further stratified to ensure enrollment of approximately 50% of subjects with BMI >32
kg/m2 and <40 kg/m2 and approximately 50% of subjects with BMI <32 kg/m2 for each dose level.

Inclusion Criteria:

- 1. Good general health.

- 2. Aged 18-44 years, inclusive, at the enrollment visit.

- 3. Intact uterus with at least one ovary.

- 4. Pap test within the last 12 months or undergo a Pap test at screening prior to
enrollment. If a potential subject states that she has had a Pap test within the last
12 months, then she will need to provide documentation of acceptable test results.

- 5. Cervical mucus score of >7, which is based on the modified Insler scoring system
during the screening cycle. The cervical mucus is collected by aspiration and the
assessment is based on the modified Insler scoring system (the volume and pH of the
mucus are not included in the total scoring) yielding a total possible score of 12 (3,
4).

- 6. Regular menstrual cycles that occur every 28 ± 7 days.

1. If subject is postpartum or post-abortal (with abortion in second trimester), she
will be required to have two normal menstrual cycles prior to screening.

2. If subject had an abortion in the first trimester, she will be required to have
at least one menstrual cycle (two menses) prior to screening.

- 7. Heterosexually abstinent or, if heterosexually active, must have undergone previous
tubal sterilization, be in monogamous relationship with a vasectomized partner, or
only use male or female condoms (use of condoms that are pre-lubricated with or
without spermicide is acceptable) for the entire duration of the study. Use of a
spermicide applied separately is not allowed. Cervical caps or diaphragms are not
allowed during study participation.

- 8. In the opinion of the investigator, able to comply with the protocol, willing to
record requested information in the daily diary, and live within the study site
catchment area or within a reasonable distance from the site.

- 9. Understand and sign an IRB approved informed consent form prior to screening
activities (including fasting blood draw).

- 10. Willing to refrain from use of skin lotions/creams/gels on area of patch
application and not use any vaginal creams, lubricants, gels, or spermicides for 3
days prior to study admission through to the end of the study.

- 11. Agree not to participate in any other clinical trials during the course of this
study.

Exclusion Criteria:

Contraindications for enrollment will be the same as those for use of combined hormonal
contraceptives as referenced in the World Health Organization (WHO) Medical Eligibility
Criteria(MEC category 1 or 2) (1), in addition to contra-indications specific to this
clinical trial including:

- 1. Known hypersensitivity or contraindication to progestins.

- 2. Known or suspected pregnancy.

- 3. Prior hysterectomy or bilateral oophorectomy.

- 4. Prior cervical surgery (LEEP, Cone biopsy, Cryosurgery).

- 5. A history (within prior 12 months) or drug or alcohol abuse.

- 6. Undiagnosed abnormal genital bleeding.

- 7. Undiagnosed vaginal discharge or vaginal lesions or abnormalities. Subjects
diagnosed at screening with a Chlamydia or gonococcus infection may not be included in
the trial unless they are treated and proof of cure is documented after treatment
(i.e. repeat test with negative results). In accordance with PI/medical designee
assessment and local standards of practice, women with a history of genital herpes can
be included if outbreaks are infrequent. Antiviral prophylactic therapy is permitted.

- 8. Uncontrolled thyroid disorder.

- 9. History or presence of dermal hypersensitivity in response to topical application.
Specifically any reaction to application of a plastic bandage (Band-Aid), surgical or
bandage tape, other skin patches, or adhesives.

- 10. Any Pap test finding that would require additional workup or treatment during the
study interval. HPV testing will not be done at screening for these subjects.

- 11. Use of an injectable hormonal contraceptive (Depo-Provera®) within the past 10
months.

- 12. Use of oral contraceptives, contraceptive implants, or other sex steroid hormones
within 30 days prior to screening visit.

- 13. Women who are breastfeeding or within 30 days of discontinuing breast feeding.

- 14. Women planning to undergo major surgery within four months of study enrollment.

- 15. Women planning pregnancy within their months of study enrollment.

- 16. Smoking in women who are ages 18-44 years old that smoke 15 cigarettes or more per
day must be evaluated by the PI for inclusion based on risk factors that would
increase their risk for CVD and thromboembolism.

- 17. Current or past deep vein thrombophlebitis or thromboembolic disorders.

- 18. History of known thrombophilia in a first-degree relative <45 years of age
suggesting familial defect in blood coagulation system, which in the opinion of the
principal investigator, suggests use of a hormonal contraceptive could pose a
significant risk.

- 19. Cerebrovascular or cardiovascular disease or increased risk for arterial
thrombosis.

- 20. History of retinal vascular lesions, unexplained partial or complete loss of
vision.

- 21. Known or suspected carcinoma of the breast, endometrium, or any other known or
suspected progestin-dependent neoplasia.

- 22. Past history of any other carcinoma (excluding basal cell carcinomas) unless in
remission for more than 5 years.

- 23. Current or past medically diagnosed severe depression, which, in the opinion of
the investigator, could be exacerbated by use of a hormonal contraceptive, unless she
is stable on antidepressant medication.

- 24. Headaches with focal neurological symptoms only in women over 35 years old.

- 25. History of cholestatic jaundice of pregnancy or jaundice with prior steroid use or
other benign or malignant liver tumors; active liver disease.

- 26. Systolic BP > 140 mm Hg and/or Diastolic blood pressure (BP) > 90 mm Hg after 5-10
minutes rest.

- 27. Clinically significant abnormal serum chemistry values according to the Principal
Investigator's judgment.

- 28. Participation in another clinical trial involving an investigational drug or
device within last 30 days (prior to screening).

- 29. Use of liver enzyme inducers within last 90 days (prior to screening) or intention
to use liver enzyme inducers during the study (see Appendix 2 Exclusionary Medication
List).

- 30. Known HIV infection.

- 31. Women at high risk of contracting HIV, e.g. women with multiple sex partners who
need to use condoms consistently, injection drug users. Women enrolled in the study,
who use condoms to protect against STIs or pregnancy, should be instructed that they
can use condoms that are pre-lubricated with spermicide or lubricated, but they cannot
use a spermicide applied separately and they should record all condom use in their
diaries.

- 32. Women who use any medications on the Exclusionary Medication List (see Appendix 2)
OR used any within the past three months prior to the screening visit.

- 33. Women with BMI ≥40 kg/m2 are excluded.